Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy

Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy

<p>Abstract</p> <p>Background</p> <p>P53 mutations are an adverse prognostic factor in esophageal cancer. P53 and KRas mutations are involved in chemo-radioresistance. Circulating anti-p53 or anti-KRas antibodies are associated with gene mutations. We studied whether an...

Full description

Bibliographic Details
Main Authors: Blanchard Pierre, Quero Laurent, Pacault Vincent, Schlageter Marie-Helene, Baruch-Hennequin Valerie, Hennequin Christophe
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Cancer
Subjects:
Esophageal cancer
Radiotherapy
Chemotherapy
p53
Ras
Online Access:http://www.biomedcentral.com/1471-2407/12/119

Internet

http://www.biomedcentral.com/1471-2407/12/119

Similar Items